Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
Public ClinicalTrials.gov record NCT04287608. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to characterize the clinical phenotype(s) of DUPIXENT®-associated conjunctivitis events. The secondary objectives of the study are to characterize the course of conjunctivitis events during the observation period and collect and assess data on treatment for conjunctivitis events and its effectiveness.
Study identification
- NCT ID
- NCT04287608
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 10, 2021 (Actual)
- Primary completion
- Mar 29, 2023 (Actual)
- Completion
- Mar 29, 2023 (Actual)
- Last update posted
- Apr 28, 2023
2021 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Study Site | Irvine | California | 92697 | — |
| Regeneron Study Site | Palo Alto | California | 94303 | — |
| Regeneron Study Site | Pasadena | California | 91105 | — |
| Regeneron Study Site | Miami | Florida | 33136 | — |
| Regeneron Study Site | New Orleans | Louisiana | 70112 | — |
| Regeneron Study Site | Baltimore | Maryland | 21205 | — |
| Regeneron Study Site | Boston | Massachusetts | 02114 | — |
| Regeneron Study Site | Great Neck | New York | 11021 | — |
| Regeneron Study Site | New York | New York | 10029 | — |
| Regeneron Study Site | Portland | Oregon | 97239 | — |
| Regeneron Study Site | Philadelphia | Pennsylvania | 19104 | — |
| Regeneron Study Site | Pittsburgh | Pennsylvania | 15213 | — |
| Regeneron Study Site | Memphis | Tennessee | 38163 | — |
| Regeneron Study Site | Dallas | Texas | 75390-8575 | — |
| Regeneron Study Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04287608, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04287608 live on ClinicalTrials.gov.